BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 45.34
-0.67 (-1.46%)
At close: Feb 13, 2026
SHA:688166 Revenue
BrightGene Bio-Medical Technology had revenue of 336.81M CNY in the quarter ending September 30, 2025, with 5.54% growth. This brings the company's revenue in the last twelve months to 1.18B, down -4.95% year-over-year. In the year 2024, BrightGene Bio-Medical Technology had annual revenue of 1.28B with 8.74% growth.
Revenue (ttm)
1.18B
Revenue Growth
-4.95%
P/S Ratio
16.24
Revenue / Employee
1.03M
Employees
1,162
Market Cap
19.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28B | 103.03M | 8.74% |
| Dec 31, 2023 | 1.18B | 162.19M | 15.94% |
| Dec 31, 2022 | 1.02B | -35.08M | -3.33% |
| Dec 31, 2021 | 1.05B | 267.03M | 34.00% |
| Dec 31, 2020 | 785.38M | 282.23M | 56.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 26.83B |
| Yili Chuanning Biotechnology | 4.74B |
| Hualan Biological Engineering | 4.27B |
| Anhui Anke Biotechnology (Group) | 2.58B |
| Tibet Cheezheng Tibetan Medicine | 2.39B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Sinocelltech Group | 1.89B |
| Inner Mongolia Furui Medical Science | 1.47B |